Nuclear factor erythroid 2-related factor 2 facilitates neuronal glutathione synthesis by upregulating neuronal excitatory amino acid transporter 3 expression.Elusive roles for reactive astrocytes in neurodegenerative diseasesCorticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degenerationDecreased metabolic response to visual stimulation in the superior colliculus of mice lacking the glial glutamate transporter GLT-1Neuron-astrocyte interactions in the regulation of brain energy metabolism: a focus on NMR spectroscopy.Normal aging modulates the neurotoxicity of mutant huntingtin.Ciliary neurotrophic factor protects striatal neurons against excitotoxicity by enhancing glial glutamate uptake.Impaired brain energy metabolism in the BACHD mouse model of Huntington's disease: critical role of astrocyte-neuron interactions.The neuroprotective agent CNTF decreases neuronal metabolites in the rat striatum: an in vivo multimodal magnetic resonance imaging study.Multifaceted roles for astrocytes in spreading depolarization: A target for limiting spreading depolarization in acute brain injury?New paradigm to assess brain cell morphology by diffusion-weighted MR spectroscopy in vivo.Targeted activation of astrocytes: a potential neuroprotective strategy.Ciliary neurotrophic factor (CNTF) activation of astrocytes decreases spreading depolarization susceptibility and increases potassium clearance.Imaging and monitoring astrocytes in health and disease.The complex STATes of astrocyte reactivity: How are they controlled by the JAK-STAT3 pathway?Astrocyte cultures exhibit P2X7 receptor channel opening in the absence of exogenous ligands.Poly(ADP-ribose)polymerase-1 modulates microglial responses to amyloid β.System xC- is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice.The JAK/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer's and Huntington's diseases.Zinc triggers microglial activationThe Nrf2 pathway as a potential therapeutic target for Huntington disease A commentary on "Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington diCalpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease.In vivo calpain/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration: implication of a calpain-mediated cleavage of active caspase-3.Insulin growth factor-1 protects against excitotoxicity in the rat striatum.IGF-1 exacerbates the neurotoxicity of the mitochondrial inhibitor 3NP in rats.Activation of astrocytes by CNTF induces metabolic plasticity and increases resistance to metabolic insults.Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging.Ciliary neurotrophic factor activates astrocytes, redistributes their glutamate transporters GLAST and GLT-1 to raft microdomains, and improves glutamate handling in vivo.Brain mitochondrial defects amplify intracellular [Ca2+] rise and neurodegeneration but not Ca2+ entry during NMDA receptor activation.Connexin 30 sets synaptic strength by controlling astroglial synapse invasion.Transplants of CNTF-producing Cells for the Treatment of Huntington's DiseaseModulation of astrocyte reactivity improves functional deficits in mouse models of Alzheimer's diseaseDiffusion-weighted magnetic resonance spectroscopy enables cell-specific monitoring of astrocyte reactivity in vivoQuestions and (some) answers on reactive astrocytesEmerging technologies to study glial cells
P50
Q24631707-FA6FDA4A-5AE8-49C3-BA04-26DE02AE937CQ26797399-2E5DB763-EE60-446F-A8E4-F46995A48995Q28581577-B3BFEEF7-21BA-4B1D-BBF6-FC39EE804E82Q28594708-56245B2F-5010-4207-BA62-7C9B327CDC84Q31065368-8FF9CD65-0E73-4B57-A8D2-754DCE814172Q33413070-447E2878-55CB-4B80-B492-8D91CA1B1B50Q33559739-5E5E82B1-4660-4134-9454-D50188AF369DQ34153434-C437702C-2CBA-4AC4-A6CD-B6C0BFB7858AQ36267231-4CAFCE64-BCAF-4D42-A441-D7858CC2E4C9Q36470874-EA130993-1BA7-45B4-828C-6E52511EC8A2Q37021697-FCBEE081-0103-4530-9523-9207DC9A4EC6Q37302851-AF82C20F-749D-45B2-964C-4EEE083CF28BQ37480238-2DE6C670-6C96-4278-A922-D895E98F57A8Q38255735-6D179326-88CB-4C99-A682-36DE1C75B8DCQ38848746-6C69995F-00E8-4A3B-BF91-D7160F8543D4Q39926483-2BFF094F-8DC6-464E-AC64-BF0DD020BA6FQ40019330-0ABB5819-EB51-4070-8CA6-196BD8282E8DQ40961556-6F6216A4-E15F-4A28-A3A1-54BCC70BF39AQ41447335-3065EDC1-3FD9-4152-93C6-D6E97D1C522AQ41842615-3EB80A93-48BC-413A-821D-86B0BDDDB8C3Q43095327-33B7CA9B-1A0C-4BB9-BBB5-A1022F7F28E8Q44495460-4AA64733-5808-4C42-88A7-E4766CD2B8E3Q44548881-10A98F6E-E5ED-4E8F-8775-CAFFA36BFEB4Q45062020-87587E34-D11A-4255-8D51-3386B848958AQ45306456-7BBD1A8C-2B27-4704-81FC-34A9DDD2A690Q48115865-97C36677-C9A9-4DD3-8399-03EC832DEE48Q48415784-61E88717-4C5A-42D5-9EC2-E8E6734C3D65Q48515330-102230CE-31C3-41CB-A60C-6DDC8C46C1CDQ48600704-56CDF59F-FFAB-4C03-8E93-AD3E3F87551CQ50683771-8E1F5A4A-4543-4E6F-926E-8B2B94F560F3Q56947084-93D079BB-CB4E-4E40-9E73-C4799C7EDA10Q57455273-AF1C79F0-16C0-4CD9-91D7-9575A896FA31Q92009032-C3705E20-CEE4-46C6-A2A8-C1900212F58CQ92719120-4438F314-4FCC-4DFF-B599-9DB98B3DC34DQ92771023-1A0C5F72-5BF3-4477-983C-1828A0E9BF0C
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Carole Escartin
@ast
Carole Escartin
@en
Carole Escartin
@es
Carole Escartin
@fr
Carole Escartin
@nl
Carole Escartin
@sl
type
label
Carole Escartin
@ast
Carole Escartin
@en
Carole Escartin
@es
Carole Escartin
@fr
Carole Escartin
@nl
Carole Escartin
@sl
prefLabel
Carole Escartin
@ast
Carole Escartin
@en
Carole Escartin
@es
Carole Escartin
@fr
Carole Escartin
@nl
Carole Escartin
@sl
P214
P269
P4285
P1053
A-1952-2010
P106
P21
P213
0000 0001 4006 1623
P214
P269
P27
P31
P3762
P3829
P4285
P496
0000-0003-3613-4118
P5552
carole-escartin
P569
1979-01-01T00:00:00Z
P734
P735
P7859
viaf-197185405